Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Nimotuzumab + Mono-chemotherapy in LAPC
NCT06422156Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Peking University Third Hospital. Primary endpoint: Progression-Free Survival at 12 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06422156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422156.